• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Pfizer's Dividend Yield Is 5.7%, Plus Humana And Shake Shack On CNBC's 'Final Trades'

    12/13/23 8:21:58 AM ET
    $CI
    $HUM
    $PFE
    $SGEN
    Medical Specialities
    Health Care
    Medical Specialities
    Health Care
    Get the next $CI alert in real time by email

    On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Shake Shack Inc (NYSE:SHAK) as his final trade.

    Shake Shack CEO Randy Garutti recently informed the board of his intention to retire in 2024 after the selection of a successor.

    The New York-based burger chain continues to see fourth-quarter revenue of $276.25 million — $281.75 million versus the consensus of $280.48 million.

    Stephen Weiss of Short Hills Capital Partners said Humana Inc. (NYSE:HUM) has 15 times earnings.

    Cigna Group (NYSE:CI) reportedly ended its attempt to negotiate an acquisition deal with rival Humana after the pair disagreed on price terms.

    Don’t forget to check out our premarket coverage here

    Jenny Harrington of Gilman Hill Asset Management said Pfizer Inc. (NYSE:PFE) has 5.7% dividend yield and 10 times earnings.

    New York-based Pfizer agreed to donate the rights of royalties from sales of cancer drug Bavencio (avelumab) to the American Association for Cancer Research to address U.S. Federal Trade Commission concerns related to its $43-billion deal to buy Seagen Inc (NASDAQ:SGEN).

    Pfizer expects to close the Seagen acquisition on Thursday, Dec. 14.

    Shannon Saccocia of Boston Private picked iShares U.S. Healthcare ETF (NYSE:IYH).

    Price Action:

    • Shake Shack shares gained 0.9% to close at $67.42 on Tuesday.
    • Humana gained 1.1% to $481.94.
    • Pfizer gained 0.2% to $28.58.
    • iShares U.S. Healthcare ETF added 0.6% during Tuesday’s session.

    Check This Out: Insiders Buying Delcath Systems And 3 Other Penny Stocks

    Image: Shutterstock

    Get the next $CI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CI
    $HUM
    $PFE
    $SGEN

    CompanyDatePrice TargetRatingAnalyst
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Shake Shack Inc.
    $SHAK
    1/20/2026$125.00Equal-Weight → Overweight
    Morgan Stanley
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Humana Inc.
    $HUM
    1/7/2026$290.00Overweight → Equal Weight
    Wells Fargo
    Shake Shack Inc.
    $SHAK
    1/6/2026$105.00Hold → Buy
    Deutsche Bank
    Shake Shack Inc.
    $SHAK
    12/18/2025$90.00Underweight → Neutral
    Analyst
    More analyst ratings

    $CI
    $HUM
    $PFE
    $SGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Cordani David bought $999,916 worth of shares (4,134 units at $241.88) (SEC Form 4)

    4 - Cigna Group (0001739940) (Issuer)

    11/3/25 2:47:56 PM ET
    $CI
    Medical Specialities
    Health Care

    President & CEO Rechtin James A. bought $1,496,984 worth of Humana Common (6,530 units at $229.25) (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    5/16/25 4:48:13 PM ET
    $HUM
    Medical Specialities
    Health Care

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CI
    $HUM
    $PFE
    $SGEN
    SEC Filings

    View All

    SEC Form 13F-HR filed by Pfizer Inc.

    13F-HR - PFIZER INC (0000078003) (Filer)

    2/12/26 4:22:51 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Humana Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HUMANA INC (0000049071) (Filer)

    2/11/26 6:40:24 AM ET
    $HUM
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Shake Shack Inc.

    SCHEDULE 13G/A - Shake Shack Inc. (0001620533) (Subject)

    2/10/26 11:17:43 AM ET
    $SHAK
    Restaurants
    Consumer Discretionary

    $CI
    $HUM
    $PFE
    $SGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, Medicare Advantage Martin Aaron was granted 17,031 units of Humana Common (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/17/26 10:38:23 AM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form 5 filed by Meyer Daniel Harris

    5 - Shake Shack Inc. (0001620533) (Issuer)

    2/6/26 4:06:16 PM ET
    $SHAK
    Restaurants
    Consumer Discretionary

    President, R&D Boshoff Christoffel covered exercise/tax liability with 12,887 shares, decreasing direct ownership by 8% to 155,645 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/2/26 5:55:49 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CI
    $HUM
    $PFE
    $SGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026

    First-in-human data for long-acting formulations of VH184, the first third-generation integrase inhibitor, and early data for capsid inhibitor VH499 to be presented, highlighting progress in ViiV's ultra long-acting pipeline 12-month data to be presented for investigational lotivibart (N6LS) + cabotegravir long-acting, evaluating feasibility of ultra long-acting dosing intervals Clinical data and real-world evidence from ViiV's innovative portfolio include insights for established INSTI-based long-acting Cabenuva (cabotegravir + rilpivirine LA) and 2-drug regimen Dovato (dolutegravir/lamivudine) ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer

    2/17/26 8:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

    BREAKWATER trial Cohort 3 analysis demonstrated statistically significant and clinically meaningful improvement in progression-free survival in BRAF V600E-mutant metastatic colorectal cancer Results reinforce potential of BRAFTOVI as a cornerstone targeted treatment, if this regimen is approved Pfizer Inc. (NYSE:PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) with a

    2/17/26 6:45:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight

    The atopic dermatitis market is expected to grow, driven by the extensive market penetration of approved therapies for moderate-to-severe atopic dermatitis and the entry of new therapies such as OX40 inhibitor (Rocatinlimab [KHK4083/AMG451]), OX40L inhibitor (Amlitelimab [KY1005]), PDE4 inhibitor (Orismilast), TSLP inhibitor (Bosakitug [BSI-045B]), IL-22RA1 blocker (Temtokibart [LP0145; LEO 138559]), IL-4Rα blocker (Rademikibart [CBP-201]), and others.LAS VEGAS, Feb. 16, 2026 /PRNewswire/ -- Recently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment practices, atopic dermatitis emerging drugs, market share of individual therapies,

    2/16/26 5:31:00 PM ET
    $ABBV
    $AMGN
    $APGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    $CI
    $HUM
    $PFE
    $SGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Humana downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Humana from Outperform to Sector Perform and set a new price target of $189.00

    2/12/26 8:16:45 AM ET
    $HUM
    Medical Specialities
    Health Care

    Pfizer downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00

    2/12/26 7:23:25 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Humana downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Humana from Equal-Weight to Underweight and set a new price target of $174.00

    2/2/26 6:49:06 AM ET
    $HUM
    Medical Specialities
    Health Care

    $CI
    $HUM
    $PFE
    $SGEN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CI
    $HUM
    $PFE
    $SGEN
    Leadership Updates

    Live Leadership Updates

    View All

    VINCENT COUNTRY SAFE ZONE ACTIVITY DAY PRESENTED BY CIGNA HEALTHCARE DELIVERS SUPER BOWL WEEK FUN, NFL FLAG FOOTBALL, AND WELLNESS TO OAKLAND STUDENTS

    Corporate, Nonprofit, and Philanthropic Partners Collaborated to Provide Transformative Experiences and Lasting Resources at Burckhalter Elementary School OAKLAND, Calif., Feb. 3, 2026 /PRNewswire/ -- Vincent Country Safe Zone Activity Day Presented by Cigna Healthcare, a flagship initiative of Love Thy Neighbor CDC co-founded by NFL Executive and Legend Troy Vincent, Sr. and his wife, author and chef Tommi A. Vincent, took place Tuesday, February 3, at Burckhalter Elementary School in Oakland, CA. The ninth annual event, themed Dreams Grow Here, delivered a full day of fun, food, wellness, and engaging sports activities, including NFL FLAG, for more than 200 Pre-K through fifth-grade studen

    2/3/26 8:17:00 PM ET
    $CI
    Medical Specialities
    Health Care

    Shake Shack Appoints Jim Taylor as Chief Commercial Officer

    Brand Brings on Seasoned Restaurant Executive to Help Scale Marketing Strategy Shake Shack Inc. ("Shake Shack" or the "Company") (NYSE:SHAK) today announced the appointment of Jim Taylor as Chief Commercial Officer, effective Tuesday, January 20. Taylor will report to Rob Lynch, CEO of Shake Shack and his role marks a new addition to the Company's leadership structure. As Chief Commercial Officer, Taylor will lead Shake Shack's marketing and culinary teams and oversee the brand's end-to-end revenue and growth strategy. "Jim is a proven leader with a track record of success across some of the most iconic brands in our industry," said Rob Lynch, Chief Executive Officer of Shake Shack. "

    1/20/26 9:15:00 AM ET
    $SHAK
    Restaurants
    Consumer Discretionary

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $CI
    $HUM
    $PFE
    $SGEN
    Financials

    Live finance-specific insights

    View All

    Humana Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Financial Guidance

    Reports 4Q25 net loss per share of $6.61 on a GAAP basis, Adjusted net loss per share of $3.96; reports full year (FY) 2025 earnings per share (EPS) of $9.84 on a GAAP basis, $17.14 on an Adjusted basis; quarterly and FY Adjusted results in line with management's expectations 4Q25 Insurance segment GAAP benefit ratio of 93.1 percent; FY 2025 Insurance segment GAAP benefit ratio of 90.4 percent, slightly better than guidance of 'the top end of the range of 90.1 percent to 90.5 percent' Introduces FY 2026 GAAP EPS guidance of 'at least $8.89'; 'at least $9.00' on an Adjusted basis; the anticipated year-over-year decline results from the Star Ratings headwind for Bonus Year 2026, net of

    2/11/26 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Shake Shack to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026

    Shake Shack Inc. ("Shake Shack" or the "Company") (NYSE:SHAK), will release fourth quarter and fiscal year 2025 financial results on February 26, 2026, before the market opens. In conjunction with the earnings release, Shake Shack will host a conference call at 8:00 a.m. ET. Hosting the call will be Rob Lynch, Chief Executive Officer. The conference call can be accessed live over the phone by dialing (877) 407-0792, or for international callers by dialing (201) 689-8263. A replay of the call will be available until March 5, 2026 by dialing (844) 512-2921 or for international callers by dialing (412) 317-6671; the passcode is 13757509. The live audio webcast of the conference call will b

    2/5/26 8:00:00 AM ET
    $SHAK
    Restaurants
    Consumer Discretionary

    The Cigna Group Reports Strong Fourth Quarter and Full Year 2025 Results, Establishes 2026 Outlook and Increases Dividend

    Total revenues for 2025 increased 11% to $274.9 billionShareholders' net income for 2025 was $6.0 billion, or $22.18 per shareAdjusted income from operations1 for 2025 was $8.0 billion, or $29.84 per share2026 adjusted income from operations1 is projected to be at least $7.950 billion, or at least $30.25 per share2Board of Directors declared an increase in the quarterly dividend to $1.56 per shareBLOOMFIELD, Conn., Feb. 5, 2026 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported 2025 results, underscoring operational discipline and the strength of its complimentary portfolio of global health businesses.

    2/5/26 6:00:00 AM ET
    $CI
    Medical Specialities
    Health Care

    $CI
    $HUM
    $PFE
    $SGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by The Cigna Group

    SC 13G - Cigna Group (0001739940) (Subject)

    11/12/24 9:55:14 AM ET
    $CI
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/16/24 4:29:43 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Humana Inc. (Amendment)

    SC 13G/A - HUMANA INC (0000049071) (Subject)

    2/14/24 10:02:59 AM ET
    $HUM
    Medical Specialities
    Health Care